Macau Casino Gambli...
Health Care: Drugs
Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ)
$10.09 -0.15 | -1.46%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 10.09 |
| 52 Week High | 13.75 |
| 52 Week Low | 5.88 |
| Avg. Daily Vol. (Mil) | 0.34 |
| Beta (3 year) | 1.40 |
| Share Related Items | |
| Mkt Cap (Mil) | 524.17 |
| Shares Out (Mil) | 51.95 |
| Float (Mil) | 45.58 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.00 |
| Current Ratio | 3.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 6.36 |
| Price/Book | 2.66 |
| Price/Cash Flow | -11.20 |
| Per Share Data | |
| Earnings | -1.23 |
| Sales | 1.59 |
| Book Value | 3.80 |
| Cash Flow | -0.90 |
| Business Summary | |
|---|---|
| Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. | |
| General Information | |
| 300 Third Street
Cambridge, MA 02142 |
|
| www.alnylam.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 115 | |
| CEO: Dr. John M. Maraganore,P | |
| Short Interest | |
| Current Month (Mil) | 5.34 |
| Previous Month (Mil) | 4.87 |
| Short Interest Ratio (Days) | 16.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -15.50 |
| Return on Investments | -26.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -64.00 |
| Profit Margin | -64.00 |
Portfolios with ALNY
- Portfolio NameUser Type
- UserThe #1 Growth Fund To Make ...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Userkite
- UserPART 6 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
- ContributorHealthcare Short Squeezes f...
- UserS.A.Chili
- UserHancock Hallock Firm
Latest ALNY Headlines from TheStreet
- 5 Stocks Insiders Love Right Now 02.24.12 | 12:02 pm
- 8 Stocks Rising on Huge Volume 02.15.12 | 02:02 pm
- 'Mad Money Lightning Round': Stay Long Sandridge 01.03.12 | 07:01 pm
- Cramer's 'Mad Money' Recap: Betting Against the Bears (Update 2) 01.03.12 | 06:01 pm
- AK Steel, Applied Materials: New Ratings 02.23.11 | 09:02 am
- Layoffs Mount in 2010: What Does It Mean for 2011? 01.06.11 | 05:01 pm
- Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results  Earnings Call Transcript 11.03.10 | 10:11 pm
- Biotech Stock Mailbag: Cyclacel Pharma 10.08.10 | 07:10 am
- Alnylam Cuts Jobs On Partner Exit 09.24.10 | 07:09 am
- Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript 08.05.10 | 12:08 am
Press Releases for ALNY
- Alnylam Announces Top-Line Results Of Phase IIb Clinical Trial Of ALN-RSV01, An Inhaled RNAi Therapeutic For The Treatment Of Respiratory Syncytial Virus (RSV) Infection - Business Wire 05.30.12 | 06:05 am
- Alnylam And PBL Sign License Agreement For Baulcombe & Hamilton RNAi Patent - Business Wire 05.23.12 | 08:05 am
- Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 04:05 pm
- Alnylam To Webcast Conference Call Discussing First Quarter 2012 Financial Results - Business Wire 04.26.12 | 04:04 pm
- Alnylam To Webcast Presentation At Future Leaders In The Biotech Industry Conference - Business Wire 04.13.12 | 04:04 pm
- Alnylam To Webcast Presentation At 11th Annual Needham Healthcare Conference - Business Wire 03.27.12 | 04:03 pm
- Alnylam Initiates Phase I Clinical Study Of ALN-TTR02, An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) - Business Wire 03.19.12 | 08:03 am
- Alnylam Retains Key Claims For Kinesin Spindle Protein (KSP) RNAi Patent In Interference Proceedings - Business Wire 03.14.12 | 06:03 am
- Alnylam To Webcast Presentation At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 04:03 pm
- Alnylam And The University Of Massachusetts Medical School Announce Tuschl I Patent Upheld In European Opposition Proceedings - Business Wire 03.01.12 | 11:03 am
Partner Headlines for ALNY
- The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases - Zacks 03.28.12 | 09:03 am
- What Alnylam Doesn't Want You To Know - Seeking Alpha 03.16.12 | 09:03 am
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Company News for February 15, 2012 - Corporate Summary - Zacks 02.15.12 | 10:02 am
- Alnylam Pharma Up 8% After Pricing Public Offering - Benzinga 02.15.12 | 09:02 am
- Alnylam Delivers In-Line Numbers - Analyst Blog - Zacks 02.13.12 | 10:02 am
- Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach - Seeking Alpha 01.30.12 | 09:01 am
- Alnylam Down to Neutral - Analyst Blog - Zacks 01.20.12 | 04:01 pm
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- Alnylam States Preclinical Data - Analyst Blog - Zacks 12.30.11 | 04:12 pm
